Drug Trial Radar · NCT02811861
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma
Last checked: Nov 20, 2026Latest source record: Feb 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,069
Actual
Start
Oct 13, 2016
Primary completion
Aug 28, 2020
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- Jun 23, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
Conditions
- Renal Cell Carcinoma
Interventions
LenvatinibDrug
EverolimusDrug
PembrolizumabDrug
SunitinibDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) by Independent Imaging Review (IIR)Time frame: From the date of randomization to the date of the first documentation of PD or date of death, whichever occurred first or up to data cutoff date 28 Aug 2020 (up to approximately 46 months)
Locations
183 sites in 20 countries. Site status is shown where the registry gives one.
Stanford School of Medicine
Stanford, California
Boca Raton Community Hospital
Boca Raton, Florida
Florida Cancer Specialists
Fort Myers, Florida
University of Miami
Miami, Florida
Mount Sinai Medical Center
Miami Beach, Florida
Florida Hospital Cancer Institute
Orlando, Florida
Florida Cancer Specialists ( North Region)
St. Petersburg, Florida
Florida Cancer Specialists
West Palm Beach, Florida
Joliet Oncology - Hematology Associates
Joliet, Illinois
Healthcare Research Network III, LLC
Tinley Park, Illinois
Health Midwest Ventures Group, Inc d/b/a HCA MidAmerica Division, LLC
Overland Park, Kansas
Cotton-Oneil Clinical Research Center
Topeka, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
Associates in Oncology & Hematology, PC
Bethesda, Maryland
Massachusetts General Hospital- MGH
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Center
Detroit, Michigan
GU Research Network
Omaha, Nebraska
Nebraska Cancer Specialists
Omaha, Nebraska
Hackensack Medical Center
Hackensack, New Jersey
Rosewell Park Cancer Institute
Buffalo, New York
Broome Oncology
Johnson City, New York
Weill Cornell Medical College New York Presbyterian Hospital
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Mission Hospital_ Cancer Care of Western North Carolina
Asheville, North Carolina
Oncology Hematology Care
Cincinnati, Ohio
Medical University of South Carolina
Charleston, South Carolina
SCRI - Tennessee Oncology
Nashville, Tennessee
Texas Oncology, P.A.
Dallas, Texas
Texas Oncology PA
Fort Worth, Texas
Texas Oncology PA - McAllen
McAllen, Texas
Texas Oncology PA - Paris
Paris, Texas
USOR Texas Oncology
The Woodlands, Texas
Texas Oncology PA - Tyler
Tyler, Texas
Royal Hobart Hospital
Hobart, Australia
Macquarie University Hospital
Macquarie Park, Australia
ICON Cancer Foundation
South Brisbane, Australia
Sunshine Hospital
St Albans, Australia
Box Hill Hospital
Box Hill, Victoria, Australia
Showing 40 of 183 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.